thiotepa has been researched along with Disease Exacerbation in 19 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study investigated interactive effects of CYP2B6 genotypes and liver metastasis on the prognosis of metastatic breast cancer patients who received combined chemotherapy of docetaxel and thiotepa." | 9.20 | The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. ( Dong, N; Lyerly, HK; Ren, J; Song, Q; Wang, X; Yang, H; Yu, J; Zhou, X, 2015) |
| "The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3)." | 6.69 | Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. ( Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M, 2000) |
| "Idarubicin is an active agent in breast cancer and is suitable for dose escalation." | 5.32 | High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ( Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I, 2003) |
| "This study investigated interactive effects of CYP2B6 genotypes and liver metastasis on the prognosis of metastatic breast cancer patients who received combined chemotherapy of docetaxel and thiotepa." | 5.20 | The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa. ( Dong, N; Lyerly, HK; Ren, J; Song, Q; Wang, X; Yang, H; Yu, J; Zhou, X, 2015) |
| "Twenty-seven children and adolescents with malignant astrocytomas [17 glioblastoma multiforme and 10 anaplastic astrocytoma (AA)] following initial tumor progression, received myeloablative chemotherapy followed by autologous marrow rescue with one of three thiotepa and etoposide-based chemotherapy regimens, administered alone (n = 11) or combined with carmustine (n = 5) or carboplatin (n = 11)." | 3.74 | Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group. ( Boyett, JM; Dhall, G; Dunkel, IJ; Finlay, JL; Gardner, SL; Goldman, S; Packer, RJ; Pollack, IF; Rosenblum, MK; Stanley, P; Wallace, D; Yates, AJ; Zimmerman, RA, 2008) |
| "The dose-limiting toxicities were interstitial pneumonitis and mucositis with moderately severe diarrhea (n = 3) and rash (n = 3)." | 2.69 | Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study. ( Blakey, D; Brettell, M; Briggs, P; Chapple, P; Eerhard, S; Gates, P; Januszewicz, EH; Juneja, S; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Seymour, JF; Toner, GC; Wolf, M, 2000) |
| "Idarubicin is an active agent in breast cancer and is suitable for dose escalation." | 1.32 | High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study. ( Bengala, C; Biadi, O; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Fogli, S; Guarneri, V; Innocenti, F; Mariani, M; Pazzagli, I, 2003) |
| "The median time to disease progression and median survival were 1." | 1.31 | Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. ( Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 14 (73.68) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sylvester, RJ | 1 |
| Oosterlinck, W | 1 |
| Holmang, S | 1 |
| Sydes, MR | 1 |
| Birtle, A | 1 |
| Gudjonsson, S | 1 |
| De Nunzio, C | 1 |
| Okamura, K | 1 |
| Kaasinen, E | 1 |
| Solsona, E | 1 |
| Ali-El-Dein, B | 1 |
| Tatar, CA | 1 |
| Inman, BA | 1 |
| N'Dow, J | 1 |
| Oddens, JR | 1 |
| Babjuk, M | 1 |
| Zhou, X | 2 |
| Wang, X | 2 |
| Song, Q | 2 |
| Yang, H | 2 |
| Zhu, X | 1 |
| Yu, J | 2 |
| Song, G | 1 |
| Di, L | 1 |
| Ren, J | 2 |
| Shao, H | 1 |
| Lyerly, HK | 2 |
| Lee, MY | 1 |
| Kim, HS | 1 |
| Lee, JY | 1 |
| Lim, SH | 1 |
| Kang, ES | 1 |
| Ko, YH | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Dong, N | 1 |
| Finlay, JL | 1 |
| Dhall, G | 1 |
| Boyett, JM | 1 |
| Dunkel, IJ | 2 |
| Gardner, SL | 1 |
| Goldman, S | 1 |
| Yates, AJ | 1 |
| Rosenblum, MK | 2 |
| Stanley, P | 1 |
| Zimmerman, RA | 1 |
| Wallace, D | 1 |
| Pollack, IF | 1 |
| Packer, RJ | 1 |
| Bengala, C | 2 |
| Danesi, R | 2 |
| Guarneri, V | 2 |
| Pazzagli, I | 2 |
| Donati, S | 2 |
| Favre, C | 2 |
| Fogli, S | 1 |
| Biadi, O | 1 |
| Innocenti, F | 2 |
| Del Tacca, M | 2 |
| Mariani, M | 1 |
| Conte, PF | 2 |
| Sayer, HG | 1 |
| Schilling, K | 1 |
| Vogt, T | 1 |
| Blumenstengel, K | 1 |
| Issa, MC | 1 |
| Mügge, LO | 1 |
| Kasper, C | 1 |
| Kath, R | 1 |
| Höffken, K | 1 |
| Lai, R | 1 |
| Abrey, LE | 1 |
| DeAngelis, LM | 1 |
| Ridola, V | 1 |
| Grill, J | 1 |
| Doz, F | 2 |
| Gentet, JC | 2 |
| Frappaz, D | 1 |
| Raquin, MA | 1 |
| Habrand, JL | 1 |
| Sainte-Rose, C | 1 |
| Valteau-Couanet, D | 1 |
| Kalifa, C | 2 |
| Gill, P | 1 |
| Litzow, M | 1 |
| Buckner, J | 1 |
| Arndt, C | 1 |
| Moynihan, T | 1 |
| Christianson, T | 1 |
| Ansell, S | 1 |
| Galanis, E | 1 |
| Tarella, C | 1 |
| Zanni, M | 1 |
| Magni, M | 1 |
| Benedetti, F | 1 |
| Patti, C | 1 |
| Barbui, T | 1 |
| Pileri, A | 1 |
| Boccadoro, M | 1 |
| Ciceri, F | 1 |
| Gallamini, A | 1 |
| Cortelazzo, S | 1 |
| Majolino, I | 1 |
| Mirto, S | 1 |
| Corradini, P | 1 |
| Passera, R | 1 |
| Pizzolo, G | 1 |
| Gianni, AM | 1 |
| Rambaldi, A | 1 |
| Tricot, G | 1 |
| Vesole, DH | 1 |
| Jagannath, S | 1 |
| Hilton, J | 1 |
| Munshi, N | 1 |
| Barlogie, B | 1 |
| Bouffet, E | 1 |
| Raquin, M | 1 |
| Rodary, C | 1 |
| Demeocq, F | 1 |
| Chastagner, P | 1 |
| Lutz, P | 1 |
| Hartmann, O | 1 |
| Hu, WW | 1 |
| Negrin, RS | 1 |
| Stockerl-Goldstein, K | 1 |
| Johnston, LJ | 1 |
| Shizuru, JA | 1 |
| Wong, RM | 1 |
| Chao, NJ | 1 |
| Long, GD | 1 |
| Feiner, RH | 1 |
| Blume, KG | 1 |
| Hawkins, D | 1 |
| Barnett, T | 1 |
| Bensinger, W | 1 |
| Gooley, T | 1 |
| Sanders, J | 1 |
| Prince, HM | 1 |
| Rischin, D | 1 |
| Toner, GC | 1 |
| Seymour, JF | 1 |
| Blakey, D | 1 |
| Gates, P | 1 |
| Eerhard, S | 1 |
| Chapple, P | 1 |
| Quinn, M | 1 |
| Brettell, M | 1 |
| Juneja, S | 1 |
| Wolf, M | 1 |
| Januszewicz, EH | 1 |
| Richardson, G | 1 |
| Scarlett, J | 1 |
| Briggs, P | 1 |
| Menconi, MC | 1 |
| Greco, F | 1 |
| Orlandini, C | 1 |
| Cairncross, G | 1 |
| Swinnen, L | 1 |
| Bayer, R | 1 |
| Rosenfeld, S | 1 |
| Salzman, D | 1 |
| Paleologos, N | 1 |
| Kaminer, L | 1 |
| Forsyth, P | 1 |
| Stewart, D | 1 |
| Peterson, K | 1 |
| Hu, W | 1 |
| Macdonald, D | 1 |
| Ramsay, D | 1 |
| Smith, A | 1 |
| Heath, JA | 1 |
| Broxson, EH | 1 |
| Dole, MG | 1 |
| Filippa, DA | 1 |
| George, D | 1 |
| Lyden, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Cohort Study of Transurethral Resection of Bladder Tumor (TURBT) Combined With Adjuvant Intravenous GC Chemotherapy to Prevent Moderate-high Recurrence and Progression Risks of Muscle-invasive Bladder Cancer[NCT02716961] | 208 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | |||
| A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco[NCT00003081] | Phase 1 | 16 participants (Anticipated) | Interventional | 1998-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for thiotepa and Disease Exacerbation
| Article | Year |
|---|---|
Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitiona | 2016 |
Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Neoplasms; Cranial Irradia | 2004 |
5 trials available for thiotepa and Disease Exacerbation
| Article | Year |
|---|---|
The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Breast Neoplasms; Cytochrome P-450 CYP2B6; Disease Prog | 2015 |
Double high-dose chemotherapy with adriamycin, paclitaxel, cyclophosphamide, and thiotepa followed by autologous peripheral blood stem cell transplantation in women with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; | 2003 |
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols | 2000 |
Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Diarrhea; | 2000 |
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Prog | 2001 |
12 other studies available for thiotepa and Disease Exacerbation
| Article | Year |
|---|---|
Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
Topics: Aged; Antineoplastic Agents, Alkylating; Biotransformation; Breast Neoplasms; Chi-Square Distributio | 2015 |
Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplas | 2015 |
Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow Transpla | 2008 |
High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2003 |
High-dose chemotherapy with autologous stem cell rescue followed by posterior fossa irradiation for local medulloblastoma recurrence or progression after conventional chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Busulfan; Cerebellar Neoplasms; Child | 2007 |
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2008 |
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Graft-versus-myeloma effect: proof of principle.
Topics: Adult; Bone Marrow Transplantation; CD3 Complex; Cyclophosphamide; Disease Progression; Female; Graf | 1996 |
Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas.
Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biops | 2000 |
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; B | 2000 |
Myeloablative chemotherapy for recurrent aggressive oligodendroglioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bone Marrow Transplanta | 2000 |
Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Ph | 2002 |